Euronext Amsterdam

Renewi plc: Delivering on Renewi’s organic growth commitments - Opening of hard plastics sorting facility Acht

Retrieved on: 
Wednesday, April 10, 2024
Plastic, Polyethylene, Euronext Amsterdam, Electronics, Research, Growth, Biofuel, Recycling

Renewi plc (“Renewi”, the “Company” or, together with its subsidiaries, the “Group”) (LSE: RWI.L: Euronext Amsterdam: RWI.AS), a leading European waste-to-product company, announces the recent opening of its hard plastics sorting facility in Acht, The Netherlands.

Key Points: 
  • Renewi plc (“Renewi”, the “Company” or, together with its subsidiaries, the “Group”) (LSE: RWI.L: Euronext Amsterdam: RWI.AS), a leading European waste-to-product company, announces the recent opening of its hard plastics sorting facility in Acht, The Netherlands.
  • With this strategic investment, first announced during its Capital Markets Day (“CMD”) in October 2023, Renewi is delivering on its sustainable organic growth objectives.
  • Hard plastics are used in a wide variety of products, including children's toys, garden furniture, electronics, household appliances, cars and containers.
  • The Acht plastics sorting facility is expected to contribute to achieving Renewi’s EBIT and topline growth targets as well as help make progress towards a more sustainable future.

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

Retrieved on: 
Monday, April 8, 2024
Disease, Ageing, Patient, Euronext Amsterdam, Clinical trial, MPH, Index, Safety, FDA, APDS, Food, Pharmaceutical industry

Pharming plans to include data from this 4–11-year-old trial in regulatory filings worldwide for the approval of leniolisib for pediatric patients with APDS, beginning in 2025.

Key Points: 
  • Pharming plans to include data from this 4–11-year-old trial in regulatory filings worldwide for the approval of leniolisib for pediatric patients with APDS, beginning in 2025.
  • Anurag Relan, MD, MPH, Chief Medical Officer of Pharming, commented:
    “This is the first clinical trial for younger pediatric patients with APDS, who have a significant unmet need for a disease modifying treatment.
  • I am pleased with the progress made in our Phase III pediatric clinical program evaluating leniolisib in children with APDS.
  • Eligible patients enrolled in either of the pediatric trials will continue to receive leniolisib for a year after the initial 12-week treatment period through an open-label extension trial.

OTC Markets Group Welcomes DSM Firmenich AG to OTCQX

Retrieved on: 
Thursday, April 4, 2024
Beauty, Health, Euronext, Euronext Amsterdam, OTCQX, Seward & Kissel, Security (finance)

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced DSM Firmenich AG (Euronext Amsterdam: DSFIR; OTCQX: DSFIY, DSMFF), a leading innovator in nutrition, health, and beauty, has qualified to trade on the OTCQX® Best Market.

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced DSM Firmenich AG (Euronext Amsterdam: DSFIR; OTCQX: DSFIY, DSMFF), a leading innovator in nutrition, health, and beauty, has qualified to trade on the OTCQX® Best Market.
  • DSM Firmenich AG upgraded to OTCQX from the Pink® Limited market.
  • DSM Firmenich AG begins trading today on OTCQX under the symbols “DSFIY and DSMFF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com .
  • Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors.

Pharming Group to participate in April investor conferences

Retrieved on: 
Wednesday, April 3, 2024
Van Lanschot Kempen, Euronext Amsterdam, Conference

Leiden, The Netherlands, April 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of April:

Key Points: 
  • Leiden, The Netherlands, April 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of April:
    23rd Annual Needham Virtual Healthcare Conference, April 8-11, 2024
    Sijmen de Vries, Chief Executive Officer, will present on Monday, April 8 at 8:45ET/14:45CEST.
  • A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website.
  • Van Lanschot Kempen Life Sciences Conference 2024, Amsterdam, NL, April 16-17, 2024
    For more information about these conferences, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at [email protected] or your Needham or Van Lanschot Kempen representative.

VEON Pays Back Outstanding Balance and Cancels its Revolving Credit Facility

Retrieved on: 
Thursday, March 28, 2024
RCF, VEON, Euronext Amsterdam, Credit

Amsterdam, 28 March 2024 – VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services (the “Company”), announces that it has repaid in full the outstanding balance of USD 805 million (principal, excluding accrued interest) under its revolving credit facility (“RCF”) and cancelled the RCF.

Key Points: 
  • Amsterdam, 28 March 2024 – VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services (the “Company”), announces that it has repaid in full the outstanding balance of USD 805 million (principal, excluding accrued interest) under its revolving credit facility (“RCF”) and cancelled the RCF.
  • The repayment of the outstanding amount and the cancellation of the RCF will reduce VEON’s interest expenses, in line with our effective cash and balance sheet management practices.
  • Elements of this press release contain or may contain “inside information” as defined under the Market Abuse Regulation (EU) No.
  • 596/2014.

VEON Announces Sale of Stake in Beeline Kyrgyzstan, increasing the focus on its large markets

Retrieved on: 
Tuesday, March 26, 2024
VEON, Completion, Chaudhary Group, Health, Education, Sale, Euronext Amsterdam, Cryptocurrency

Amsterdam, 26 March 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces that it has signed an agreement for the sale of its 50.1% indirect stake in Beeline Kyrgyzstan to CG Cell Technologies, which is wholly owned by CG Corp Global.

Key Points: 
  • Amsterdam, 26 March 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces that it has signed an agreement for the sale of its 50.1% indirect stake in Beeline Kyrgyzstan to CG Cell Technologies, which is wholly owned by CG Corp Global.
  • The sale is a part of VEON’s strategy to simplify the Group’s structure and focus on its large markets where it can create scale with its DO1440 digital operator model, providing digital services in finance, entertainment, healthcare and education.
  • The transaction values Beeline Kyrgyzstan’s business at 3.4x 2023 EBITDA (pre-IFRS16).
  • CG Corp Global issued the following statement on the agreement: “We are very pleased to become a major investor in the Kyrgyzstan telecommunications market with the purchase of the majority stake in Beeline Kyrgyzstan.

New Amsterdam Invest N.V. will publish audited annual report 2023 on 29 April 2024 D.V.

Retrieved on: 
Monday, April 8, 2024
Operation, One half, Annual report, Euronext Amsterdam, NAI, AGM, Acquisition, Renting

AMSTERDAM, April 8, 2024 /PRNewswire/ -- New Amsterdam Invest N.V. (the "Company", or "New Amsterdam Invest", or "NAI"), a commercial real estate company listed on Euronext Amsterdam, announces it rescheduled publication of its audited annual report 2023 to 29 April 2024 and AGM to 21 June 2024.

Key Points: 
  • AMSTERDAM, April 8, 2024 /PRNewswire/ -- New Amsterdam Invest N.V. (the "Company", or "New Amsterdam Invest", or "NAI"), a commercial real estate company listed on Euronext Amsterdam, announces it rescheduled publication of its audited annual report 2023 to 29 April 2024 and AGM to 21 June 2024.
  • Until 2 June 2023 the Company operated as a SPAC and only per that date acquired its operating companies.
  • The Board of NAI is strongly committed to deliver the market and its investors a comprehensive set of audited accounts and hence rescheduled publication of the 2023 annual report, originally due today, to 29 April 2024.
  • The AGM agenda will be published on 29 April and the new AGM date has been set at 21 June 2024.

dsm-firmenich announces repurchase of 1.5m shares to cover share plans

Retrieved on: 
Monday, April 8, 2024
Agreement, Annual, Euronext Amsterdam, Share repurchase

KAISERAUGST, Switzerland and MAASTRICHT, Netherlands, April 8, 2024 /PRNewswire/ -- dsm-firmenich today announces that, starting April 8, 2024, it intends to repurchase 1,500,000 ordinary shares to cover commitments under the Group's share-based compensation plans.

Key Points: 
  • KAISERAUGST, Switzerland and MAASTRICHT, Netherlands, April 8, 2024 /PRNewswire/ -- dsm-firmenich today announces that, starting April 8, 2024, it intends to repurchase 1,500,000 ordinary shares to cover commitments under the Group's share-based compensation plans.
  • The share repurchase is equivalent to approximately €156 million based on the closing price of the dsm-firmenich ordinary share on Euronext Amsterdam on April 4, 2024.
  • The program consists of an on-market share repurchase of 500,000 shares, followed by a repurchase of 1,000,000 shares by means of an equity forward transaction.
  • Other than the delivery of the shares under the equity forward transaction, the share repurchase program is anticipated to be completed in Q2 2024.

ONWARD® Medical Publishes Closing of Accelerated Bookbuild Offering and Public Offering in France

Retrieved on: 
Monday, March 25, 2024
Offerings, Private, Brussels Stock Exchange, Euronext, DSM-IV codes, NOT, Euronext Amsterdam, Movement, SCI, Security (finance)

EINDHOVEN, the Netherlands, March 25, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disorders, announces today the closing of its previously announced private placement with institutional investors, certain founders, certain members of management, and certain members of the Board of Directors (the “Private Placement”) and of its separate public offering via the PrimaryBid platform with retail investors in France (the “Public Offer” and together with the Private Placement the “Offerings”).  The gross proceeds from the Offerings amount to €20 million. 

Key Points: 
  • OTHER RESTRICTIONS ARE APPLICABLE.
  • PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
  • As of today, the new shares issued pursuant to the Offerings are admitted to listing and trading on Euronext Brussels and Euronext Amsterdam.
  • This press release does not constitute, contain, or form part of an offering of securities in any jurisdiction.

Cabka Receives B Score in Debut CDP Climate Assessment

Retrieved on: 
Monday, March 25, 2024
Sustainability, Natural Resources, CDP, RTP, Climate change, Euronext Amsterdam, Gold

Cabka N.V. (together with its subsidiaries “Cabka”, or the “Company”), a company specialized in transforming hard-to-recycle plastic waste into innovative Reusable Transport Packaging (RTP), listed at Euronext Amsterdam, announces its first participation in the Climate Disclosure Project (CDP) and the notable B score achieved in the 2023 assessment.

Key Points: 
  • Cabka N.V. (together with its subsidiaries “Cabka”, or the “Company”), a company specialized in transforming hard-to-recycle plastic waste into innovative Reusable Transport Packaging (RTP), listed at Euronext Amsterdam, announces its first participation in the Climate Disclosure Project (CDP) and the notable B score achieved in the 2023 assessment.
  • CDP's climate assessment serves as the gold standard for measuring corporate climate performance, offering valuable insights to investors, businesses, and policymakers worldwide.
  • Cabka's B score reflects the company's concerted efforts to address climate challenges.
  • "Receiving a B score from CDP not only reaffirms our position as responsible corporate citizens but also motivates us to continue promoting the transformation of our industry towards a circular economy."